gemcitabine has been researched along with hydroxyurea in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonnac, L; Clouser, CL; Daly, MB; Kim, B; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS; Roth, ME; Xie, J | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chubb, S; Grindey, GB; Heinemann, V; Hertel, LW; Plunkett, W; Sen, A; Xu, YZ | 1 |
| Bianchi, V; Borella, S; Calderazzo, F; Chieco Bianchi, L; Ferraro, P; Reichard, P | 1 |
| Lawrence, TS; McGinn, CJ; Shewach, DS | 1 |
| Chitambar, CR; Elford, HL; Myette, MS | 1 |
| Chitambar, CR; Myette, MS; Wereley, JP; Wong, SJ | 1 |
| Kelly, S; Nguyen, M; Sun, D; Urrabaz, R; Weitman, S | 1 |
| Liu, X; Mo, X; Qiu, W; Yen, Y; Zhou, B | 1 |
| Chow, W; Doroshow, JH; Frankel, P; Gandara, D; Lenz, HJ; Leong, L; Longmate, J; Margolin, K; Morgan, R; Newman, EM; Raschko, J; Shibata, S; Somlo, G; Synold, T; Twardowski, P; Yen, Y | 1 |
| Ostruszka, LJ; Shewach, DS | 1 |
| Jiang, R; Sairenji, T; Satoh, Y; Zhang, JL | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Funamizu, N; Kamata, Y; Lacy, CR; Manome, Y; Misawa, T; Uwagawa, T; Yanaga, K | 1 |
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Bai, J; Fu, S; Guan, R; Huang, Y; Ji, W; Jin, Y; Meng, X; Quan, C; Sun, D; Sun, W; Yu, L; Yu, Y; Zhang, C; Zhao, Y; Zhu, J | 1 |
| Gaur, S; Horne, D; Hu, S; Hu, W; Smith, DL; Su, L; Synold, TW; Wu, J; Yen, Y; Yip, ML; Yuan, YC; Zhou, B | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Bonazzi, V; Daignault, SM; Fernando, M; Gabrielli, B; Haass, NK; Lanagan, C; Larsen, JE; Nazareth, D; Oo, ZY; Proctor, M; Škalamera, D; Snell, C; Stevenson, AJ; Walpole, S | 1 |
| Akahoshi, K; Ban, D; Fujii, M; Kato, T; Kudo, A; Ogawa, K; Ogura, T; Ono, H; Tanabe, M; Tanaka, S | 1 |
| Alyahya, MY; Bhadra, S; Khan, S; Samuel, RE; Xu, YJ | 1 |
2 review(s) available for gemcitabine and hydroxyurea
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Radiosensitizing nucleosides.
Topics: Animals; Deoxycytidine; Gemcitabine; Humans; Hydroxyurea; Nucleosides; Pyrimidines; Radiation-Sensitizing Agents; Thymidine; Vidarabine | 1996 |
2 trial(s) available for gemcitabine and hydroxyurea
| Article | Year |
|---|---|
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; California; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Hydroxyurea; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2002 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
22 other study(ies) available for gemcitabine and hydroxyurea
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
Topics: Anti-HIV Agents; Azacitidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Ribonucleotide Reductases; Structure-Activity Relationship | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Topics: Cell Line; Cytidine; Deoxycytidine; Deoxycytosine Nucleotides; DNA; Gemcitabine; Humans; Hydroxyurea; Oxidation-Reduction; Ribonucleoside Diphosphate Reductase; Ribonucleotides; Thymine Nucleotides | 1990 |
Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cells, Cultured; Cytidine; Deoxycytidine; Gemcitabine; Humans; Hydroxyurea; In Vitro Techniques; Prodrugs; Ribonucleotide Reductases; Zidovudine | 1994 |
Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Topics: Antineoplastic Agents; Benzamidines; Cell Division; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Gallium; Gemcitabine; Humans; Hydroxamic Acids; Hydroxyurea; Oximes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured | 1998 |
Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Deoxycytidine; DNA, Neoplasm; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydroxyurea; Leukemia, Lymphoid; Ribonucleotide Reductases; Tumor Cells, Cultured | 1999 |
Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Cycle; Cytarabine; Deoxycytidine; DNA Ligase ATP; DNA Ligases; Dose-Response Relationship, Drug; Enzyme Activation; Fluorouracil; Gemcitabine; Humans; Hydroxyurea; Tumor Cells, Cultured | 2002 |
Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance.
Topics: Chromosome Banding; Chromosomes, Human, Pair 2; Deoxycytidine; DNA; Drug Resistance; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Amplification; Gene Expression Regulation, Enzymologic; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Karyotyping; Promoter Regions, Genetic; Protein Subunits; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Staining and Labeling; Transcription Factors; Transcription, Genetic; Translocation, Genetic; Tumor Cells, Cultured | 2001 |
The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
Topics: Antineoplastic Agents; Aphidicolin; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; DNA, Neoplasm; Enzyme Inhibitors; Gemcitabine; Glioblastoma; Humans; Hydroxyurea; Nucleic Acid Synthesis Inhibitors; Pyrimidine Nucleosides; Ribonucleotide Reductases | 2003 |
Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji.
Topics: Antiviral Agents; Burkitt Lymphoma; Cell Line, Transformed; Cell Line, Tumor; Clone Cells; Deoxycytidine; Drug Resistance, Viral; Enzyme Inhibitors; Gemcitabine; Genome, Viral; Herpesvirus 4, Human; Humans; Hydroxyurea; Ribonucleotide Reductases; Virus Latency | 2004 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Topics: Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hydroxyurea; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA Interference; Snail Family Transcription Factors; Transcription Factors; Vimentin; Zinc Finger E-box-Binding Homeobox 1 | 2012 |
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; DNA, Neoplasm; Eukaryotic Translation Initiation Factor 5A; Female; Gemcitabine; Gene Amplification; Histones; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Micronuclei, Chromosome-Defective; Myeloid Cell Leukemia Sequence 1 Protein; N-Myc Proto-Oncogene Protein; Nuclear Proteins; Oncogene Proteins; Ovarian Neoplasms; Peptide Initiation Factors; Real-Time Polymerase Chain Reaction; RNA-Binding Proteins | 2013 |
A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatography, High Pressure Liquid; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Flow Cytometry; Gemcitabine; Half-Life; Humans; Hydroxyurea; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred NOD; Mice, SCID; Mutagenesis, Site-Directed; Mutation; Neoplasms; Protein Conformation; Ribonucleotide Reductases; Small Molecule Libraries; Structure-Activity Relationship; Surface Plasmon Resonance; Tandem Mass Spectrometry; Thiazoles | 2013 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors | 2019 |
Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
Topics: Aged; Cell Line, Tumor; Cell Survival; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Up-Regulation | 2021 |
Replication stress induced by the ribonucleotide reductase inhibitor guanazole, triapine and gemcitabine in fission yeast.
Topics: Cell Cycle Proteins; Checkpoint Kinase 2; Deoxycytidine; DNA Replication; Enzyme Inhibitors; Gemcitabine; Guanazole; Humans; Hydroxyurea; Pyridines; Ribonucleotide Reductases; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Thiosemicarbazones | 2022 |